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Abstract
Background: Biochemical changes associated with multiple sclerosis (MS), and its various clinical forms have not
been characterized well. Therefore, we investigated the biochemistry of MS in relation to its natural history using
targeted lipidomics platforms.
Methods: Cross-sectional serum samples from 24 secondary progressive (SPMS), 100 relapsing remitting (RRMS), 19
primary progressive MS (PPMS), and 55 age-matched control subjects were analyzed by flow injection tandem mass
spectrometry for very long chain fatty acid (VLCFA) containing phosphatidyl ethanolamines (PtdEtn), plasmalogen
ethanolamines (PlsEtn) and for novel anti-inflammatory gastrointestinal tract acids (GTAs). Changes in analyte levels
relative to healthy controls were correlated with the disease stage and disease duration.
Results: RRMS subjects having <13 years disease duration had elevated levels (p < 0.05) of anti-inflammatory
metabolites (GTAs) and normal levels (p > 0.05) of mitochondrial stress biomarkers (VLCFA-PtdEtn), compared to
controls. SPMS subjects had statistically similar levels of anti-inflammatory metabolites (GTAs), elevated
mitochondrial stress metabolites (VLCFA-PtdEtn) and elevated peroxisomal metabolites (PlsEtn) compared to
controls
(p < 0.05). RRMS subjects with > = 13 years disease duration exhibited metabolic profiles intermediate between
short-duration RRMS and SPMS, based on statistical significance. Therefore, RRMS cohort appear to comprise of two
metabolically distinct subpopulations. The key clinical discriminator of these two groups was disease duration. PPMS
patients exhibited metabolic profiles distinct from RRMS and SPMS.
Conclusions: These data indicate that inflammation and mitochondrial stress are intricately involved in the etiology
of MS and that progression in MS can potentially be monitored using serum metabolic biomarkers.
Background
Multiple sclerosis (MS) is a central nervous system dis-
ease that progresses to severe disability. The relatively
young age of onset of the disease and the progressive de-
bilitation place a severe burden on national health sys-
tems and the families of the affected person.
MS manifests in several forms. Clinically Isolated Syn-
drome (CIS) is the first manifestation of MS-like signs
and symptoms, usually followed by another attack at
which a clinical diagnosis of MS is made. Most patients
are initially diagnosed with relapsing remitting MS
(RRMS). The RRMS form is characterized by sudden
relapses punctuated by short or long-term remissions.
Eighty percent of RRMS patients eventually progress to
secondary progressive MS (SPMS), which has a progres-
sive course resulting in severe, irreversible debilitation
[1]. Primary progressive MS (PPMS) is a progressive type
of MS without an initial relapsing and remitting period.
The diagnosis of MS is a daunting and lengthy task
as definitive diagnostic tests are not available. The
physician has to rely on the clinical presentation and
Magnetic Resonance Imaging (MRI) evidence of the
appearance of lesions separated in time and space for
diagnosis [2–4]. Other manifestations of the disease (e.g.,
optic-spinal form) and diseases with similar symptoms
make MS diagnosis challenging [4–6]. Phadke and Best
[5] stated that the only proven diagnosis of MS is through
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autopsy, highlighting the difficulty in diagnosing MS.
Therefore, the need for effective and definitive diagnostic
tests for MS cannot be overemphasized.
The biggest hindrance for the development of a diag-
nostic or predictive test for MS is the lack of complete
understanding of its causes and disease progression
process. The pathological process in MS is a dynamic
process involving changes in cellular turnover and me-
tabolism. Accordingly, a novel concept in disease risk
prediction and diagnosis is monitoring the metabolic
trail elicited by these changes. We have previously re-
ported on the discovery of a novel class of anti-
inflammatory hydroxylated long chain fatty acids called
Gastro-intestinal Tract Acids (GTAs) present in human
serum [7]. These metabolites were decreased in diseases
such as colorectal cancer and inflammatory bowel disease
[8]. In addition, we have also reported mitochondrial
stress induced changes in the levels of ethanolamine phos-
pholipids [9] in autism, a disease characterized by central
nervous system (CNS) inflammation [9]. Since MS is a
progressive disorder with a long disease duration, and
given that inflammation [10, 11] and oxidative stress-
induced mitochondrial dysfunction [12–14] are implicated
in MS, metabolic signatures of these events could possibly
be used to monitor the underlying disease processes and
could be helpful in assessing response to treatment. Hence
the objective of this study is to investigate the biochemical
changes associated with MS and its clinical forms in rela-
tion to the natural history of the disease.
Methods
Study subjects
A cohort of MS patients representing the three forms of
the disease and age matched controls was selected for the
study. Serum samples were collected, processed and
stored in a consistent manner using standardized proto-
cols and operating procedures at BioServe Biotechnolo-
gies, Inc., Laurel, Maryland, USA (formerly Genomics
Collaborative Inc., a subsidiary of SeraCare Life Sciences
Inc.). Collection protocols were approved by the Western
Institutional Review Board, and all samples were properly
consented. The research did not contravene the principles
of the Declaration of Helsinki (http://www.wma.net/en/
30publications/10policies/b3/index.html). Detailed clinical
and diagnostic data were obtained from the suppliers of
serum samples. The number of patients with RRMS,
PPMS, and SPMS were 100, 19 and 24 respectively. Con-
trol samples were from 55 healthy subjects.
Lipidomic analyses
Three metabolite classes, namely phosphatidylethanol-
amines (PtdEtn), plasmalogen ethanolamines (PlsEtn), and
a unique class of hydroxylated unsaturated very long chain
fatty acids called Gastrointestinal Tract Acids (GTAs)
were examined. Serum samples were stored at −80 °C
until analysis. Sample extraction and analysis was carried
out essentially as described earlier [15, 9], utilizing flow in-
jection tandem mass spectrometry and monitored under
negative atmospheric pressure chemical ionization mode
(APCI). The method was based on multiple reaction mon-
itoring (MRM) of parent/fragment ion transitions specific
for each metabolite. All samples were analyzed in a ran-
domized blinded manner. Results were based on ratios of
integrated analyte peak area to the internal standard
(PtdEtn and PlsEtn) or based on the calculated concentra-
tion extrapolated from an external standard curve (GTA).
Statistical analyses
Log transformed relative intensities of each analyte was
used for statistical analyses. Analysis of variance
(ANOVA) with post hoc Sidak test or student’s t-test was
used for statistical analysis. For both ANOVA and stu-
dent’s t-test, p < 0.05 was considered significant. All com-
putations were done using STATA version 13 (Stata,
RRID:nlx_156918) or Microsoft Excel, 2010.
Results
Patient characteristics
Mean ages in years (95 % CI) of controls, RRMS, SPMS,
and PPMS cohorts were 48.3 (45.7–50.8), 46.6 (44.7–
48.5), 51.3 (47.2–55.4), and 54.7 (50.6–58.8), respect-
ively. Percentages of males and females in control,
RRMS, SPMS and PPMS groups in that order were 22
and 78 %, 10 and 90 %, 33 and 67 %, and 42 and 58 %,
respectively. Mean disease durations (95 % CI) in RRMS,
SPMS, and PPMS patients were 9.6 (7.9–11.3), 11.9
(9.4–14.4) and 12.7 (7.9–17.6), respectively.
Ethanolamine phospholipids
Table 1 summarizes the observed changes in PtdEtn spe-
cies according to MS disease state and duration. Most of
the PtdEtn containing very long chain fatty acids (VLCFA)
assayed were elevated in SPMS vs controls (p < 0.05)
(Table 1a). In comparison to the controls, only 11 VLCFA
species were significantly elevated in RRMS patients with
a lesser disease duration (<13 y) (Table 1b). However,
when disease duration in RRMS exceeded 13 y, the num-
ber of significantly elevated VLCFA species (vs controls)
increased to 27 (Table 1c). The number of VLCFA species
significantly elevated (vs controls) in PPMS patients were
not as high as SPMS (Table 1d) and tended to be similar
to the RRMS >13 y category (Table 1c and Table 1d). Sig-
nificant elevation of 28:0 containing PtdEtn (PtdEtn 16:0/
28:0), was observed in SPMS compared to the controls
and RRMS < 13 y (Fig. 1a). When RRMS patients were di-
vided into two groups based on disease duration, the
group having the longer disease duration (> = 13 y) had
levels not different from SPMS (p > 0.05) (Fig. 1a). In
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Table 1 Relative changes in fatty acid classes at sn-2 position of phosphatidyl ethanolamines in Multiple Sclerosis
a. SPMS patients compared to healthy controls
Chain length→ 18 20 22 24 26 28 30 32 34 36 38 40
No. of double bonds ↓
0 16/18↑ 16/18↑ 16/18↑ 16/18↑ 16/18↑ 16↑ 16/18↑ 16/18↑
1 18↑ 16/18↑ 18↑ 18↑ 16↑ 16↑ 16/18↑ 16/18↑
2 16↑ 16↑ 16↑ 16↑ 16↑
3 16/18↑ 16/18↑ 16/18↑ 16/18↑ 16/18↑ 16/18↑ 16/18↑ 16↑ 16↑ 16↑ 16/18↑ 16/18↑
4 16/18↑ 16/18↑ 16/18↑ 16/18↑ 16/18↑ 18↑ 16↑ 16↑ 16/18↑ 16/18↑ 16/18↑
5 16/18↑ 16/18↑ 16/18↑ 16/18↑ 16↑ 16↑ 16↑ 16↑ 18↑ 16/18↑ 16/18↑
6 16/18↑ 16/18↑ 16/18↑ 16/18↑ 18↑ 16↑ 18↑ 16↑
b. RRMS patients with a disease duration <13 years compared to healthy controls
Chain length → 18 20 22 24 26 28 30 32 34 36 38 40






5 16↑ 16/18↑ 16↑
6 18↑ 16↑ 16↑
c. RRMS patients with a disease duration > =13 years compared to healthy controls
Chain length → 18 20 22 24 26 28 30 32 34 36 38 40
No. of double bonds ↓
0 18↑ 16↑ 16↑ 16↑
1 18↑ 16↑
2 16↑ 16/18↑ 18↑ 16↑ 16↑
3 16↑ 16↑ 18↑ 16↑ 18↑ 16↑
4
5 16↑ 16↑
6 16/18↑ 16/18↑ 16↑ 16↑ 16↑
d. PPMS patients compared to healthy controls
Chain length → 18 20 22 24 26 28 30 32 34 36 38 40
No. of double bonds ↓
0 18↑ 18↑ 18↑ 16/18↑ 18↑ 16/18↑
1 18↑ 18↑
2 18↑ 18↑
3 16↑ 16↑ 16↑
4 18↑ 16↑ 16↑ 18↑
5
6 16/18↑ 16/18↑ 16/18↑ 16↑ 18↑
Fatty acids at sn-2 position in phosphatidyl ethanolamines are categorized according to their number of double bonds and chain length. Carbon chain length is
given in columns and number of double bonds are given in rows. Fatty acid chain length at sn-1 position is given within the cells as 16 or 18, indicating 16:0 and
18:0 respectively. Up and down arrows indicate a significant increase or decrease in relative intensity (ratio to internal standard) respectively, compared to the
control group at p < 0.05 (student’s t-test). a. SP-MS patients compared to healthy controls, b. RRMS patients with a disease duration <13 years compared to
healthy controls, c. RRMS patients with a disease duration >=13 years compared to healthy controls, d. PPMS patients compared to healthy controls
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general, the level of circulating VLCFA in RRMS tended
to increase with their disease duration (data not shown).
The ratio of PtdEtn containing Docosahexaenoic acid
(DHA, 22:6) to PtdEtn containing the precursor (18:3)
was significantly enhanced in RRMS > = 13 y, SPMS and
PPMS compared to controls (Fig. 1b). This enhancement
was seen even in early stages (<13 y disease duration) of
RRMS (Fig. 1b). DHA biosynthesis occurs via chain
elongation and desaturation of 18:3 (n-3) to 24:6 in the
endoplasmic reticulum followed by beta oxidation to
22:6 in the peroxisome [16]. These observations indicate
that enhanced flux through this pathway occurs early in
the disease process. Plasmalogen biosynthesis involves
partial beta-oxidation of VLCFA to medium chain fatty
acids prior to conversion to its alcohol followed by
elongation to predominately 16 and 18 carbon alcohols
that eventually get incorporated at the sn-1 position
[17]. Because of the direct role played by peroxisomes in
Fig. 1 a. Phosphatidyl ethanolamine 16:0/28:0 levels in Multiple Sclerosis. Cross sectional serum samples from each of the clinical groups were
subjected to lipidomic analysis utilizing tandem mass spectrometry. Bars represent mean value of the ratio of phosphatidyl ethanolamine 16:0/
28:0 to the internal standard. Error bars represent ± SEM. RRMS <13 Y: Relapsing Remitting Multiple Sclerosis having less than 13 years of disease
duration; RRMS > = 13 Y: Relapsing Remitting Multiple Sclerosis with >= 13 years of disease duration; SPMS: Secondary Progressive Multiple Sclerosis;
PPMS: Primary Progressive Multiple Sclerosis. Letters shared in common indicate no significant difference between the respective groups ( p < 0.05,
ANOVA followed by post hoc Sidak test of log normalized internal standard corrected analyte values). b. Ratio of Phosphatidyl ethanolamine 16:0/22:6
to phosphatidyl ethanolamine 16:0/18:3 in Multiple Sclerosis. Cross sectional serum samples from each of the clinical groups were subjected to
lipidomic analysis utilizing tandem mass spectrometry. Bars represent mean value of phosphatidyl ethanolamine 16:0/22:6 normalized to phosphatidyl
ethanolamine 16:0/18:3. Error bars represent ± SEM. RRMS <13 Y: Relapsing Remitting Multiple Sclerosis having less than 13 years of disease duration;
RRMS > = 13 Y: Relapsing Remitting Multiple Sclerosis with >= 13 years of disease duration; SPMS: Secondary Progressive Multiple Sclerosis; PPMS:
Primary Progressive Multiple Sclerosis. * p < 0.05 vs controls (Student’s test). c. Plasmalogen ethanolamine 16:0/22:6 levels in Multiple Sclerosis. Cross
sectional serum samples from each of the clinical groups were subjected to lipidomic analysis utilizing tandem mass spectrometry. Bars represent
mean value of the ratio of plasmalogen ethanolamine 16:0/22:6 to the internal standard. Error bars represent ± SEM. RRMS <13 Y: Relapsing Remitting
Multiple Sclerosis having less than 13 years of disease duration; RRMS > = 13 Y: Relapsing Remitting Multiple Sclerosis with >= 13 years of disease
duration; SPMS: Secondary Progressive Multiple Sclerosis; PPMS: Primary Progressive Multiple Sclerosis. Letters shared in common indicate no
significant difference between the respective groups ( p < 0.05, ANOVA followed by post hoc Sidak test of log normalized internal standard corrected
analyte values). d. Ratio of Plasmalogen ethanolamine 16:0/22:6 to phosphatidyl ethanolamine 16:0/18:3 in Multiple Sclerosis. Cross sectional serum
samples from each of the clinical groups were subjected to lipidomic analysis utilizing tandem mass spectrometry. Bars represent mean value of
plasmalogen ethanolamine 16:0/22:6 normalized to phosphatidyl ethanolamine 16:0/18:3. Error bars represent ± SEM. RRMS <13 Y: Relapsing Remitting
Multiple Sclerosis having less than 13 years of disease duration; RRMS > = 13 Y: Relapsing Remitting Multiple Sclerosis with >= 13 years of disease
duration; SPMS: Secondary Progressive Multiple Sclerosis; PPMS: Primary Progressive Multiple Sclerosis. # p = 0.09 vs controls (Student’s test)
Senanayake et al. BMC Neurology  (2015) 15:154 Page 4 of 10
plasmalogen biosynthesis, plasmalogen levels can be
used as markers of peroxisomal function and activity.
All plasmalogen species measured were significantly ele-
vated in SPMS compared to the controls. As can be seen
in Fig. 1c, DHA containing plasmalogen (PlsEtn 16:0/
22:6), a representative plasmalogen, was significantly ele-
vated in SPMS and RRMS > = 13 y (vs controls). When
the ratio of PlsEtn 16:0/22:6 to PtdEtn 16:0/18:3 was
taken in order to normalize for dietary variations of
16:0/18:3, the ratio was elevated only in SPMS patients
relative to controls, confirming the enhanced synthesis
of PlsEtn 16:0/22:6 in SPMS (Fig. 1d).
Gastrointestinal tract acids
Anti-inflammatory long-chain fatty acids (GTAs) were
significantly elevated in short duration RRMS (disease
duration <13 years) compared to SPMS (Fig. 2a). Table 2
shows statistically significant changes in levels of GTAs
with different chain lengths and degree of unsaturation,
in each clinical form, compared to controls. As shown in
Table 2, significant elevation of 11 out of 34 GTAs ana-
lyzed were seen in RRMS patients with disease duration
less than 13 years (vs controls). Eight out of 34 GTAs
were significantly reduced in SPMS patients while one
GTA was elevated in PPMS (vs controls). These trends
are illustrated in Fig. 2a for a selected GTA (GTA465/
403). SPMS patients demonstrated significant decrease
of this GTA compared to RRMS < 13 y, while there was
no significant difference between > = 13 y and SPMS or
between > = 13 y and PPMS. Effect of disease duration
was further illustrated by the negative correlation ob-
served between disease duration and the level of
GTA465/403 in RRMS patients (Fig. 2b).
Correlation of the ratio of VLCFA and GTA to disease
duration in RRMS
Since there was a reciprocal trend in VLCFA and GTA
levels in RRMS patients in relation to disease duration,
the ratio of these two biomarkers was examined to see
whether there was a time-dependent pattern that can in-
dicate any transitional stage in the biochemical state of
RRMS patients. When the disease duration was plotted
against the ratio of PtdEtn 16:0/28:0 to GTA465/403, it
tended to decrease up to approximately 13 years and
then tended to increase with the remaining disease dur-
ation (data not shown). Moreover, there was a strong
negative correlation between PtdEtn 16:0/28:0 and GTA
465/403 in the first year of RRMS diagnosis (r2 = 0.47).
Discussion
Primary findings in this study are three-fold. Firstly, sig-
nificant elevations of multiple species of VLCFA-PtdEtn
were observed in SPMS patients, relative to age-matched
healthy controls. Similar increases were observed in
RRMS patients also, but a comparatively lesser number
of VLCFA-PtdEtns were involved. However, RRMS pa-
tients with longer disease duration (>13 y) had more
VLCFA-PtdEtn species elevated than RRMS patients
with lesser disease duration (<13 y). Secondly, PlsEtn, es-
pecially those containing DHA, were significantly in-
creased in SPMS compared to controls. PlsEtn levels did
not differ in RRMS relative to controls, irrespective of
the disease duration. Thirdly, anti-inflammatory mole-
cules (GTAs) were significantly reduced in SPMS relative
to the controls. In contrast, RRMS patients had signifi-
cantly elevated levels of these molecules, compared to
Fig. 2 a. Gastrointestinal tract acid (465/403) levels in Multiple
Sclerosis. Cross sectional serum samples from each of the clinical
groups were subjected to lipidomic analysis utilizing tandem mass
spectrometry. Bars represent the mean concentration of
gastrointestinal tract acid (abbreviated as MRM 465/403). Error bars
represent ± SEM. RRMS <13 Y: Relapsing Remitting Multiple Sclerosis
having less than 13 years of disease duration; RRMS > = 13 Y:
Relapsing Remitting Multiple Sclerosis with >= 13 years of disease
duration; SPMS: Secondary Progressive Multiple Sclerosis; PPMS:
Primary Progressive Multiple Sclerosis. Letters shared in common
indicate no significant difference between the respective groups
(P < 0.05, ANOVA followed by post hoc Sidak test of log normalized
internal standard corrected analyte values). b. Correlation of
gastrointestinal tract acid (465/403) to the disease duration in
relapsing remitting Multiple Sclerosis. Mean concentration of
gastrointestinal tract acid 465/403 in serum as measured by tandem
mass spectrometry in relapsing remitting multiple sclerosis patients
with the same disease duration (rounded down to years) were
plotted against the disease duration. Slope of the curve that best fits
the data was −0.025 and R2 = 0.2019
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controls and levels tended to decrease with advancing
disease duration.
Our study population included a cohort of RRMS,
SPMS, and PPMS patients varying in disease duration
and age. The control group consisted of age and gender
matched individuals with no known morbidity at the
time of blood collection. Therefore, metabolic differ-
ences observed in MS clinical entities compared to the
controls represent underlying metabolic abnormalities.
Although the study is cross sectional, which is a limita-
tion, study subjects represented disease duration varying
from 0–34 years in RRMS and from 2–26 years in
SPMS, enabling us to correlate the metabolic profiles
with the natural history of the disease.
VLCFA are fatty acids having carbon chains longer
than 22 carbons. Circulating levels of these fatty acids
are elevated in a number of disorders, for example in X-
linked adrenoleukodystrophy (X-ALD) [18, 19] and Zell-
weger spectrum disorders [20, 21]. ATP-binding cassette
sub-family D member 1 (adrenoleukodystrophy protein),
a very long chain acyl-CoA transporter in the peroxi-
somal membrane, is deficient in X-ALD [19], whereas in
Zellweger spectrum disorders, multiple peroxisomal pro-
teins are deficient [22]. PlsEtn, which are produced
solely by the peroxisomes, are characteristically reduced
in all these diseases [23, 24] as a result of the defective
peroxisomes. However, compared to controls, PlsEtn
levels were not deficient either in RRMS or in SPMS pa-
tients in our study, implying that peroxisomal deficits, as
found in the aforementioned diseases, are not the cause
of VLCFA elevation in MS patients in our study.
Long chain fatty acids, such as palmitate (16:0) and
oleic (18:1) are β-oxidized in mitochondria whereas
VLCFA are β-oxidized in peroxisomes to medium chain
fatty acids (MCFA) [25]. MCFA are then transported to
mitochondria for further oxidation [25]. The acetyl-CoA
units produced as a result of peroxisomal β-oxidation
are either utilized for anabolic reactions within the per-
oxisomes such as for plasmalogen synthesis [24, 17],
shuttled out to cytosol for chain elongation of fatty acids
(the process of synthesizing VLCFA) [26], or become
substrates for other synthetic reactions, for example
cholesterol synthesis.
Significance of this peroxisomal-mitochondrial inter-
action in VLCFA metabolism is elaborated in following
studies. If fatty acid trafficking to the mitochondria is
blocked by inhibiting Carnitine Palmitoyl Transferase I
(CPT I), the oxidation of long chain fatty acids (for ex-
ample 16:0 or 18:0) in peroxisomes increases in isolated
rat hepatocytes [27]. Diversion of polyunsaturated fatty
acids to peroxisomes for metabolism has been shown
when mitochondrial β-oxidation is inhibited in rats [28].
Furthermore, drug induced inhibition of mitochondrial
function in rats enhanced peroxisomal β-oxidation gene
expression [29]. However, since peroxisomal metabolism
has an anabolic outcome, the acetyl-CoA produced is
used for chain elongation of fatty acid [26]. Elongation
of fatty acids is a major source of circulating VLCFA
[30]. Therefore, elevation of circulating VLCFA is a con-
sequence of mitochondrial β-oxidation deficiency.
We have previously shown that glutamate can dose
dependently inhibit β-oxidation of palmitate [9]. Poten-
tial mechanisms included reduced processing of acetyl-
CoA via the tricarboxylic acid (TCA) cycle due to the
inhibition of citrate formation and/or changes in the
NADH/NAD+ ratio due to efflux of aspartate [31]. Both
mechanisms lead to inhibition of β-oxidation [9] increas-
ing the accumulation of acyl-CoA in the cytoplasm. Car-
nitine is used both for the removal of excess acyl-CoA
from mitochondria as well as for fatty acid transport into
Table 2 Relative changes in gastrointestinal tract acids in Multiple Sclerosis
Carbon length Number of→ double bonds/free hydroxyl groups 1 ↓ C28 C30 C32 C34 C36
1/0 ↑RR < 13y
1/1 ↑RR < 13y ↑RR < 13y
1/2 ↓SP ↑RR < 13y ↑RR < 13y
2/0 ↑RR < 13y ↑RR < 13y
2/1 ↑RR < 13y,↓SP ↓SP ↑RR < 13y ↓SP
3/0 ↑RR < 13y, ↑PP
3/1 ↓SP ↓SP
3/2 ↑RR < 13y ↓SP
4/0
4/1 ↓SP
Gastrointestinal tract acids are categorized according to their chain length, number of double bonds and the number of free hydroxyl groups. Carbon chain
length is given in columns and the number of double bonds and free hydroxyl groups are given in rows, separated by a slash. Up or down arrows indicate a
significant increase or decrease in serum concentration respectively, compared to the control group at p < 0.05 (Student’s t- test). RR < 13y; Relapsing remitting
Multiple Sclerosis patients with a disease duration <13 years, RR > 13y; Relapsing remitting Multiple Sclerosis patients with a disease duration > =13 years, SP;
Secondary progressive Multiple Sclerosis patients, PP; Primary progressive Multiple Sclerosis patients
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mitochondria, so the shifting of this equilibrium towards
acetyl-carnitine could possibly reduce the availability of
carnitine [32] for CPT I-dependent fatty acid transport
across outer mitochondrial membrane, further reducing
fatty acid oxidation. Cytosolic acetyl-CoA is also used
for malonyl-CoA production [33, 34], which provides
additional impetus to inhibit mitochondrial fatty acid
oxidation [35].
VLCFA are high affinity ligands for Peroxisome
Proliferator-Activated Receptor α (PPAR-α) [36]. In-
creased peroxisomal activity along with increased avail-
ability of substrate (acetyl-CoA produced during
peroxisomal β-oxidation) will drive PlsEtn synthesis [9],
elevating their levels. Although not observed in RRMS pa-
tients where VLCFA were not upregulated as much as in
SPMS, elevated PlsEtn levels were seen in SPMS patients.
Therefore, chronic elevation of certain VLCFA during the
RRMS stage as shown in this study can be expected to
lead to an eventual increase in PlsEtn in SPMS.
Moreover, DHA containing PtdEtn and PlsEtn were
also elevated in SPMS patients, but not in RRMS pa-
tients. Conversion of 24:6 to 22:6 by β-oxidation, which
is the final step in DHA synthesis, occurs in peroxisomes
[37]. DHA synthesis is regulated by PlsEtn, as demon-
strated by the reduction of DHA levels in PlsEtn defi-
cient cells [38]. When PlsEtn was stimulated in these
cells by adding a precursor, DHA synthesis also in-
creased [38]. Therefore, upregulation of PlsEtn synthesis,
along with global enhancement of fatty acid elongation,
can be expected to trigger DHA synthesis, elevating its
levels as seen in SPMS.
Consequently, all lipid derangements observed in MS
patients can be explained by the reduction of fatty acid β-
oxidation due to subtle mitochondrial dysfunction (Fig. 3).
Evidence supporting this hypothesis come from our previ-
ous in vitro studies using HepG2 cells that showed dose
dependent reduction of palmitate oxidation by glutamate
[9]. These cells also had increased levels of VLCFA and
DHA containing PlsEtn [9]. Interestingly, L-carnitine sup-
plementation has been reported to ameliorate fatigue in
MS patients [39, 40], lending further support to this hy-
pothesis. Moreover, a patient presenting with a relapsing
and remitting demyelinating disorder similar to multiple
sclerosis was found to have defects in mitochondrial β-
oxidation and accumulated acylcarnitines in blood [41].
The patient improved with the supplementation of L-
carnitine and riboflavin in the diet along with a low-fat,
high-carbohydrate diet [41]. These clinical examples also
provide indirect evidence for a likely reduction of mito-
chondrial fatty acid β-oxidation in MS.
Altered mitochondrial structure, molecular and bio-
chemical abnormalities, impaired Complex I activity and
impaired bioenergetics has been demonstrated in MS
patients, as reviewed by Morris and Berk et al. [42].
Their review provide ample evidence that mitochondrial
dysfunction is a frequent finding in MS. Mitochondrial
dysfunction could be secondary to oxidative damage of
this organelle. Oxidized macromolecules have been
Fig. 3 Schematic representation of the proposed relationship between Multiple Sclerosis, mitochondrial insufficiency and metabolic signatures.
Underlying mitochondrial insuffciency possibly aggravated by an insult reduces mitochondrial capacity resulting in an increased flux through the
peroxisomal β-oxidation system. This enhanced peroxisomal activity leads to elevated VLCFA and plasmalogens. Elevated VLCFA could result in CNS
inflammation and demyelination. This metabolic derangement is hypothesized to start in early RRMS stage, culminating as a distinct metabolic
phenotype in the SPMS stage. RRMS: Relapsing Remitting Multiple Sclerosis; SPMS: Secondary Progressive Multiple Sclerosis; VLCFA: Very Long Chain
Fatty Acids; GTA: Gastrointestinal Tract Acids; DHA: Docosahexaenoic acid
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demonstrated in active MS lesions and are associated
with apoptotic oligodendrocytes and areas of neurode-
generation in MS, as reviewed by Haider [43]. Oxidative
stress in mitochondria could be induced by reactive oxy-
gen and nitrogen species from activated microglia [13,
43]. Oxidative stress in turn could also induce pro-
inflammatory genes, initiating a self-perpetuating cycle
[42]. Therefore, an initial inflammatory trigger or incipi-
ent mitochondrial dysfunction triggered by environmen-
tal factors could initiate this vicious cycle.
VLCFA are known to cause inflammation and demye-
lination [44]. Chronic elevated levels of VLCFA can in-
duce inflammation in the brain [24, 45]. Indeed, VLCFA
infusion has induced lypooxygenases in the brain in ex-
perimental animals [46]. Demyelination is a hallmark of
X-ALD, wherein deleterious effects of abnormally high
VLCFA levels are well established. Sphingolipids that
contain VLCFA are a major component of myelin, along
with cholesterol and phospholipids [47]. They also exist
in outer plasma membrane mostly in lipid rafts, in con-
junction with cholesterol [48]. Elevation of VLCFA can
therefore be expected to change sphingolipid compos-
ition. Perturbations in sphingolipid metabolism are
known in MS [49]. Consequently, it can be speculated
that there is a link between VLCFA, sphingolipids, and
inflammation in MS.
Potential sources of elevated VLCFA are the liver and
CNS. The liver is a source of many circulating lipids. As
described above, myelin in the CNS is enriched with
sphingolipids containing VLCFA. Demyelination can
therefore possibly cause a local elevation of VLCFA, al-
though it is unclear whether peripheral levels would be
elevated. Also, activated microglia that emerge during
demyelination produce copious amounts of glutamate
[50] which can induce mitochondrial dysfunction. Mito-
chondrial dysfunction can lead to VLCFA accumulation
as described elsewhere, possibly initiating and perpetuat-
ing a vicious cycle.
All three clinical forms of MS in this study had higher
PtdEtn 16:0/28:0 than controls (p < 0.05, student’s t-test).
However, an increase in the number of elevated VLCFA-
PtdEtn species in patients with longer disease duration
in RRMS, and an even higher number of elevated species
in SPMS, may indicate that deranged VLCFA metabol-
ism is an accumulating deficit in MS. In contrast, the
opposite behavior of GTAs in these two patient categor-
ies is thought to be due to changes in the anti-
inflammatory response. GTAs are novel fatty acids
known to have anti-inflammatory effects in vitro [7] and
are associated with a protective phenotype in various
malignant tumors [24]. Higher GTA levels (p < 0.05 vs.
controls) in early RRMS (<13 y disease duration) and
low GTA levels (p < 0.05 vs. controls) observed in SPMS
is suggestive of a protective response in early relapsing
remitting phase, that eventually diminish in the progres-
sive phase. Although unconfirmed, reduction in GTAs in
the latter stages of RRMS could be ascribed to patho-
physiological inability to sustain this protective response.
The reversal of the ratio of PtdEtn 16:0/28:0 to GTA
465/403 at about 13 years of disease duration in the
RRMS group (data not shown) indicates that RRMS is
comprised of two metabolically distinct sub-groups with
the disease duration as the key discriminator between
the subgroups (<13 y and > = 13 y). This is further con-
firmed by the differences in the total number of elevated
VLCFA-PtdEtn and by significant differences in the
levels of PtdEtn 16:0/28:0 and in GTA 465/403, observed
between these two sub-groups. Although highly specula-
tive without a longitudinal study, the presence of meta-
bolically distinct subpopulations in RRMS, with the
subgroup with a disease duration > = 13 y being closer
to SPMS (in terms of sum of elevated VLCFA-PtdEtn,
PtdEtn 16:0/28:0 and GTA 465/403), indicate that transi-
tion from RRMS to SPMS can be monitored using these
metabolic changes.
Longitudinal studies will be needed to overcome the
limitations posed by cross-sectional nature of the RRMS
samples. Smaller sample sizes in SPMS and PPMS pa-
tient groups limits the generalization of the results. Lar-
ger and longitudinal studies are planned to overcome
these limitations.
Conclusions
In summary, we have demonstrated that MS pathotypes
have distinct metabolic profiles, characterized by overt
changes in VLCFA and PlsEtn metabolism, and changes
in putative anti-inflammatory molecules, GTAs. Inter-
action between these metabolites may predict the course
of the disease. Further research, particularly longitudinal
studies, are needed to verify this hypothesis.
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